Silence Therapeutics.
UK business
- Reports this week
- 0
- Active events
- 0
- Connections
- 24
What's happening
One to three months ago
Gone quiet
No new reports in 90+ days-
FDA turned back ITM's experimental treatment, while Silence Therapeutics' divesiran was identified as a potential competitive threat to rusfertide.Some support1 report
-
Silence Therapeutics received designations for its divesiran program from the FDA, leading to stock price movement.Some support1 report
-
Silence Therapeutics is listed on the Nasdaq stock exchange.Some support1 report
-
Silence Therapeutics was required to file disclosures with the Securities and Exchange Commission on July 31, 2026.Some support1 report
-
Richard Griffiths holds the largest shareholder stake in Silence Therapeutics, according to reports from July 2025.Speculative1 report
-
Silence Therapeutics reported its financial results from London on August 7, 2025.Some support1 report
-
Morgan Stanley, Silence Therapeutics, and H.C. Wainwright are involved in a conference on September 2, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Silence Therapeutics this week
News at the entities that move Silence Therapeutics most-
Morgan Stanley OperationalGPIX holds short derivative positions with Morgan Stanley, listing Apple and Amazon as large U.S. stock holdings.Moves Silence Therapeutics
-
FDA StructuralPresident Boakai is addressed by community petitions, and Rudolph Merab is named as the Managing Director of the FDA.Moves Silence Therapeutics
-
Securities and Exchange Commission StructuralClorox traded on the NYSE and filed documents with the SEC, while also appointing Ernst & Young LLP as its independent auditor.Moves Silence Therapeutics
-
Cantor Fitzgerald Mentioned togetherCantor Fitzgerald, led by Gerard Casey, has established an operational presence in Ireland, with offices in Dublin, Limerick, and Cork.Moves Silence Therapeutics
-
MarketBeat Mentioned togetherMarketBeat used its stock screener tool to highlight Walmart.Moves Silence Therapeutics
-
Nasdaq StructuralAnthropic debuted on Nasdaq, while Andrew Benson spoke to CNN about Hill's share tracking services.Moves Silence Therapeutics
Connections
The 10 strongest of 24, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Merck Structural
Merck acquired Silence Therapeutics, establishing a parent-subsidiary relationship.
-
William P. Blair Operational
William Blair actively influences the market perception and rating of Silence Therapeutics.
-
Morgan Stanley Operational
Morgan Stanley actively provides positive investment ratings and target price boosts for Silence Therapeutics.
-
FDA Structural
Silence Therapeutics is seeking regulatory designations and approval from the FDA for its divesiran program.
-
Securities and Exchange Commission Structural
Silence Therapeutics is required to file disclosures with the Securities and Exchange Commission.
-
Nasdaq Structural
The company is listed on the Nasdaq stock exchange, relying on its market infrastructure for public trading.
-
William Blair Mentioned together
William Blair downgraded shares of Silence Therapeutics.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provides financial coverage and issues ratings for Silence Therapeutics.
Show all 10 connections
-
Jefferies Financial Group Operational
Jefferies Financial Group issued a rating cut regarding Silence Therapeutics.
-
MarketBeat Mentioned together
MarketBeat reports average stock ratings and financial analysis for Silence Therapeutics.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
3 events- FDA turned back ITM's experimental treatment, while Silence Therapeutics' divesiran was identified as a potential competitive threat to rusfertide.
- Silence Therapeutics received designations for its divesiran program from the FDA, leading to stock price movement.
- Silence Therapeutics is listed on the Nasdaq stock exchange.
July 2026
1 eventShow 1 earlier month
June 2026
3 events- Richard Griffiths holds the largest shareholder stake in Silence Therapeutics, according to reports from July 2025.
- Silence Therapeutics reported its financial results from London on August 7, 2025.
- Morgan Stanley, Silence Therapeutics, and H.C. Wainwright are involved in a conference on September 2, 2025.